Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study
Background: To compare adverse event (AE) profiles between patients with prostate cancer receiving triplet therapy (docetaxel, androgen receptor signaling inhibitors [ARSIs], and androgen deprivation therapy [ADT]) and those receiving docetaxel-based therapy (docetaxel and ADT). Additionally, we sou...
Saved in:
| Main Authors: | Fumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, Hidetsugu Takahashi, Masaki Hashimoto, Shuhei Hara, Wataru Fukuokaya, Yu Imai, Kosuke Iwatani, Taro Igarashi, Mahito Atsuta, Kojiro Tashiro, Masaya Murakami, Shunsuke Tsuzuki, Brendan A. Yanada, Toshihiro Yamamoto, Kenichi Hata, Hiroki Yamada, Jun Miki, Takahiro Kimura |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Prostate International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888224000850 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis
by: Chengwen Sun, et al.
Published: (2025-07-01) -
The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience
by: Qiyan Cai, et al.
Published: (2025-07-01) -
Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach
by: Almudena Zapatero, et al.
Published: (2025-07-01) -
A novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence-free survival in patients with prostate cancer
by: Desheng Zhu, et al.
Published: (2025-08-01) -
Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression
by: S. I. Kutukova, et al.
Published: (2025-07-01)